$12.90
1.18% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
IL0011407140
Symbol
URGN
Sector
Industry

UroGen Pharma Ltd. Stock price

$12.90
-1.37 9.60% 1M
-2.06 13.77% 6M
-2.10 14.00% YTD
-2.19 14.51% 1Y
-5.04 28.09% 3Y
-11.08 46.21% 5Y
-1.08 7.73% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.15 1.18%
ISIN
IL0011407140
Symbol
URGN
Sector
Industry

Key metrics

Market capitalization $536.95m
Enterprise Value $394.08m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.64
P/S ratio (TTM) P/S ratio 6.32
P/B ratio (TTM) P/B ratio 17.32
Revenue growth (TTM) Revenue growth 17.22%
Revenue (TTM) Revenue $85.01m
EBIT (operating result TTM) EBIT $-79.69m
Free Cash Flow (TTM) Free Cash Flow $-83.62m
Cash position $241.90m
EPS (TTM) EPS $-3.27
P/E forward negative
P/S forward 5.68
EV/Sales forward 4.17
Short interest 15.66%
Show more

Is UroGen Pharma Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

UroGen Pharma Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a UroGen Pharma Ltd. forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a UroGen Pharma Ltd. forecast:

Buy
83%
Hold
17%

Financial data from UroGen Pharma Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
85 85
17% 17%
100%
- Direct Costs 8.61 8.61
4% 4%
10%
76 76
20% 20%
90%
- Selling and Administrative Expenses 102 102
19% 19%
120%
- Research and Development Expense 52 52
2% 2%
62%
-78 -78
6% 6%
-92%
- Depreciation and Amortization 1.45 1.45
17% 17%
2%
EBIT (Operating Income) EBIT -80 -80
5% 5%
-94%
Net Profit -114 -114
5% 5%
-134%

In millions USD.

Don't miss a Thing! We will send you all news about UroGen Pharma Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

UroGen Pharma Ltd. Stock News

Positive
Seeking Alpha
29 days ago
UroGen Pharma stock is a strong buy due to its innovative RTGel technology and promising pipeline, including JELMYTO and UGN-102, targeting urological cancers. URGN's JELMYTO shows impressive clinical results with a 58% complete response rate for low-grade upper tract urothelial cancer, demonstrating long-lasting effects. URGN's diverse pipeline, including UGN-301 for high-grade NMIBC, position...
Neutral
Business Wire
30 days ago
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in fireside chats at the following investor conferences in September: H.C. Wainwright 26th Annual Global Investment Conference – September 9-11th, 2024 Firesid...
Neutral
Seeking Alpha
about 2 months ago
UroGen Pharma Ltd. (NASDAQ:URGN ) Q2 2024 Earnings Call August 13, 2024 10:00 AM ET Company Participants Vincent Perrone - Head, Investor Relations Liz Barrett - President and Chief Executive Officer Mark Schoenberg - Chief Medical Officer David Lin - Chief Commercial Officer Dong Kim - Chief Financial Officer Conference Call Participants Tara Bancroft - TD Cowen Raghuram Selvaraju - H.C.
More UroGen Pharma Ltd. News

Company Profile

UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology. Its pipeline includes upper tract urothelial carcinoma, low grade non muscle invasive bladder cancer, carcinoma in situ of the bladder, and overactive bladder. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Head office Israel
CEO Elizabeth Barrett
Employees 201
Founded 2004
Website www.urogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today